Neuraxis (NRXS) Non-Current Debt (2022 - 2024)
Neuraxis (NRXS) posted Non-Current Debt of $38797.0 for Q2 2024, down 73.8% sequentially from $148062.0 in Q4 2023, and little changed YoY from $38797.0 in Q3 2023.
Neuraxis (NRXS) Non-Current Debt (2022 - 2024) Analysis & Trends
Neuraxis has reported Non-Current Debt for 3 years, with the latest figure at $38797.0 in Q2 2024.
- Quarterly Non-Current Debt changed 0.0% year-over-year to $38797.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $38797.0 (changed 0.0% YoY) and the FY2023 annual result came in at $148062.0, down 27.0% from the prior year.
- Non-Current Debt declined to $38797.0 in Q2 2024 per NRXS's latest filing, from $148062.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $2.6 million in Q1 2023 and troughed at $38797.0 in Q2 2023.
- A 3-year average of $545456.3 and a median of $171155.0 in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt fell 27.0% in 2023, then changed 0.0% in 2024.
- Over 3 years, Non-Current Debt stood at $202834.0 in 2022, then retreated by 27.0% to $148062.0 in 2023, then sank by 73.8% to $38797.0 in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $38797.0, $148062.0, and $194248.0 for Q2 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 38,797.00 |
| Dec 31, 2023 | 148,062.00 |
| Sep 30, 2023 | 194,248.00 |
| Jun 30, 2023 | 38,797.00 |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 202,834.00 |